Eurand to Present At Lazard Capital Markets 4th Annual Healthcare
AMSTERDAM, The Netherlands, Nov. 20, 2007 (PRIME NEWSWIRE) -- Eurand
N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops
enhanced pharmaceutical and biopharmaceutical products based on its
proprietary drug formulation technologies, announced today that it is
scheduled to present at the upcoming Lazard Capital Markets 4th
Annual Healthcare Conference in New York, NY on Wednesday, November
28, 2007. Gearoid Faherty, Chief Executive Officer of Eurand, will be
Event: Lazard Capital Markets 4th Annual Healthcare Conference
Date: Wednesday, November 28, 2007
Time: 2:30 pm ET (8:30 pm CET)
Place: New York Palace Hotel, New York, NY
An audio Web cast of the Company's presentation will be available by
accessing the investor relations section of Eurand's Web site at
http://www.eurand.com. A replay of the presentation will be available
through December 18, 2007.
Eurand is a specialty pharmaceutical company that develops enhanced
pharmaceutical and biopharmaceutical products based on its
proprietary drug formulation technologies. Eurand has had four
products approved by the FDA since 2001 and has a pipeline of product
candidates in development for itself and its collaboration partners.
Eurand has completed two phase III clinical trials on its lead
product candidate, Zentase, for the treatment of Exocrine Pancreatic
Insufficiency and filed a rolling NDA for this product which the
company anticipates to complete by the end of 2007. Eurand's
technology platforms include bioavailability enhancement of poorly
soluble drugs, customized release, taste-making/fast-dissolving
formulations and drug conjugation.
Eurand is a global company with facilities in the USA and Europe. For
more information, visit Eurand's website at www.eurand.com.
This release, and oral statements made with respect to information
contained in this release, constitutes forward-looking statements.
Such forward-looking statements include those which express plan,
anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact
including, but not limited to our plans for our NDA filing,
enrollment and future plans for our clinical trials, progress of and
reports of results from clinical studies, clinical development plans
and product development activities. The words "potentially," "could,"
"calls for" and similar expressions also identify forward-looking
statements. These statements are based upon management's current
expectations and are subject to risks and uncertainties, known and
unknown, which could cause actual results and developments to differ
materially from those expressed or implied in such statements.
Factors that could affect actual results include risks associated
with the possibility that the FDA refuses to approve our NDA; the
outcome of any discussions with the FDA; and unexpected delays in
preparation of materials for submission to the FDA as a part of our
NDA filing. Forward-looking statements contained in this press
release are made as of this date, and we undertake no obligation to
publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise. Actual events could
differ materially from those anticipated in the forward-looking
CONTACT: Eurand N.V.
Mario Crovetto, Chief Financial Officer
+39 02 95428 521
The Ruth Group
--- End of Message ---
845 Center Drive Vandalia, Ohio USA
WKN: A0MSPK; ISIN: